Natural Capsules
Q2 revenue of ₹51.15 Cr (+12% YoY) and a narrower loss, but US capsule demand is absent, HPMC guidance is dropped, and FY27 API revenue guidance is cut to ₹12-15 Cr.
ALFA Concalls
Every earnings call, live and summarised
Earnings calls
Every Natural Capsules earnings call we streamed: the live audio and our summary of what management said.
Q2 revenue of ₹51.15 Cr (+12% YoY) and a narrower loss, but US capsule demand is absent, HPMC guidance is dropped, and FY27 API revenue guidance is cut to ₹12-15 Cr.
Q2 revenue of ₹51.15 Cr (+12% YoY) and a narrower loss, but US capsule demand is absent, HPMC guidance is dropped, and FY27 API revenue guidance is cut to ₹12-15 Cr.
FY27 API revenue ₹12-15 Cr (from ₹70-80 Cr); subsidiary cash break-even FY28 at ~₹120 Cr revenue.
Natural Capsules Ltd reported Q4 FY26 revenue of ₹58.45cr (up 55% QoQ). Full-year FY26 revenue grew 11% to ₹187.20cr, though the company posted a net loss of ₹24.66cr.
Natural Capsules reports Q4FY26 revenue of ₹58.45 Cr (+30% Y-o-Y) while facing a PAT loss of ₹4.98 Cr. Strategy focuses on steroidal API scaling and HPMC capsule expansion.
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.